enGene Holdings Inc (ENGN)

Healthcare | Biotechnology
Latest reporting period: 2026-01-31

Latest Quarter

2026-01-31

Revenue

$0.0

Net Income

-$29.8M

Operating Margin

N/A

Free Cash Flow

-$101M

Debt / Assets

24.3%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for enGene Holdings Inc (ENGN).
Income Statement (Quarterly) 2026-01-31 2025-01-31 2024-10-31 2024-07-31
Revenue 0 0 0 0
Cost of Revenue 189,000 0 0 82,000
Gross Profit -189,000 0 0 -82,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 8,930,000 6,003,000 7,700,000 4,682,000
Operating Expenses 30,996,000 26,613,000 17,455,000 16,759,000
Operating Income -31,185,000 -26,613,000 -17,455,000 -16,759,000
Interest Expense 732,000 752,000 756,000 751,000
Income Before Tax -29,752,000 -24,598,000 -15,280,000 -14,177,000
Income Tax Expense 0 18,000 19,000 -29,000
Net Income -29,752,000 -24,616,000 -15,299,000 -14,148,000
Per Share
EPS -0.44 -0.48 -0.03 -0.32
EPS Diluted 0.00 0.00 0.00 0.00